Conflict of interest: Nothing to declare.
ADHD and secondary ADHD criteria fail to identify many at-risk survivors of pediatric ALL and brain tumor†
Article first published online: 18 FEB 2011
Copyright © 2011 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 57, Issue 1, pages 110–118, 15 July 2011
How to Cite
Kahalley, L. S., Conklin, H. M., Tyc, V. L., Wilson, S. J., Hinds, P. S., Wu, S., Xiong, X. and Hudson, M. M. (2011), ADHD and secondary ADHD criteria fail to identify many at-risk survivors of pediatric ALL and brain tumor. Pediatr. Blood Cancer, 57: 110–118. doi: 10.1002/pbc.22998
- Issue published online: 9 MAY 2011
- Article first published online: 18 FEB 2011
- Manuscript Accepted: 2 DEC 2010
- Manuscript Received: 23 SEP 2010
- National Institute of Drug Abuse. Grant Number: F32DA024503
- NIH Cancer Center Support CORE Grant. Grant Number: CA21765
- American Lebanese Syrian Associated Charities (ALSAC)
- cognitive assessment;
Post-treatment attention problems experienced by pediatric cancer survivors have been described as similar to symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) experienced in physically healthy children. Accordingly, the objectives of this study were to: (a) estimate the rate of occurrence of ADHD and secondary ADHD (SADHD) in a sample of pediatric cancer survivors, (b) compare the rate of ADHD/SADHD among survivors to the prevalence of ADHD in the general population, and (c) examine clinical correlates of ADHD/SADHD in this sample.
Survivors of pediatric ALL or brain tumor (n = 100) participated in an assessment of attention including a Computerized Performance Measure [Conners' Continuous Performance test-II (CPT-II)], parent and self-report measures (Conners 3), and a structured diagnostic interview for ADHD and other psychological disorders [Diagnostic Interview for Children and Adolescents-IV (DICA-IV)].
Binomial tests revealed that the rate of ADHD/SADHD in our sample (9%) was significantly greater than the lower limits of ADHD prevalence among children in the US (3%; P < 0.001), while no difference was identified compared to the upper limits of ADHD prevalence (7%; P > 0.05). Many additional survivors (>25% of the sample) obtained clinical elevations on Conners 3 scales but did not meet ADHD/SADHD criteria.
Attentional deficits experienced by pediatric cancer survivors do not appear to resemble the clinical presentation of ADHD or SADHD. Many survivors with cognitive and behavioral difficulties related to attention were not identified using this diagnostic approach. Findings offer needed clarification to guide researchers and clinicians in conceptualizing, assessing, and intervening on attentional late effects. Pediatr Blood Cancer 2011;57:110–118. © 2011 Wiley-Liss, Inc.